Kuiper vs Starlink: Bezos and Musk's space rivalry enters new orbit
The mission, called Kuiper Atlas 1, lifted off from Cape Canaveral Space Force Station in Florida at 7:00 pm local time (2300 GMT), aboard a United Launch Alliance (ULA) Atlas V rocket that will carry 27 satellites into orbit.
A previous attempt was scrubbed earlier this month due to bad weather.
Project Kuiper, a subsidiary of the online retail giant founded by Jeff Bezos, is playing catch-up with Starlink — SpaceX's sprawling network of internet satellites that has reshaped the sector and handed Musk significant geopolitical clout.
The US$10 billion (RM43.3 billion) initiative plans to deploy 3,200 satellites into low Earth orbit — the region of space up to 1,200 miles (1,900 kilometres) above the planet — with hopes of going live later this year.
Pricing has not yet been revealed, but Amazon has pledged it will align with its reputation as a low-cost retailer.
'Atlas V is on its way to orbit to take those 27 Kuiper satellites, put them on their way, and really start this new era in internet connectivity,' said ULA's Caleb Weiss.
With yesterday's launch, Amazon formally enters a crowded and fast-growing field that includes not just Starlink but other emerging players in the satellite internet race.
SpaceX launched the first batch of Starlink satellites in 2019 and now boasts more than 6,750 operational units, serving over five million customers worldwide — by far the sector's dominant force.
Starlink has also provided crucial internet access in disaster and war zones, including Morocco after its devastating 2023 earthquake and on the frontlines in Ukraine's war against Russia.
Amazon plans to accelerate launches in the coming months and years, with more than 80 flights booked through United Launch Alliance (a Boeing-Lockheed Martin joint venture), France's Arianespace, Bezos's own Blue Origin, and even Musk's SpaceX.
Its satellites will gradually join the swelling ranks of low Earth orbit, alongside Starlink, Europe's OneWeb, and China's Guowang constellation.
The increasing crowding of this orbital neighbourhood has sparked concerns about congestion, potential collisions, and disruptions to astronomical observations.
The expanding role of private companies in space has also raised thorny political questions, especially as Musk's influence stretches beyond business into politics and diplomacy.
Musk has sent mixed signals on Starlink's future role in Ukraine, where it remains vital to Kyiv's war effort — a conflict that Musk ally US President Donald Trump has vowed to bring to an end. — AFP
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
an hour ago
- The Star
JPMorgan eyes new research frontier with coverage of private firms, source says
FILE PHOTO: A J.P. Morgan logo is seen in New York City, U.S. January 10, 2017. REUTERS/Stephanie Keith/File Photo (Reuters) -JPMorgan Chase has begun publishing research notes on prominent private companies transforming industries, a person familiar with the matter told Reuters on Friday. With many industry-leading private companies delaying public listings, they are attracting a growing share of investor capital, prompting institutional investors to track them more closely at earlier stages. Companies such as ChatGPT-maker OpenAI, Elon Musk's SpaceX and TikTok-parent Bytedance now hold valuations that rival or surpass several major S&P 500 firms, blurring the distinction between public and private market influence. The largest U.S. lender released its first report on OpenAI, the company that spurred Wall Street's AI gold rush, according to an internal memo seen by Reuters. Unlike traditional research notes, these brokerage reports will not feature estimates, price targets or ratings, Hussein Malik, head of global research said in the memo, which highlighted AI and software as core areas for private company coverage. "Private companies are becoming increasingly relevant to various industries, especially in the new economy space," Malik said. "The goal of this offering is to support our investor clients by providing structured information and tracking, offering deeper insights into key disruptors and their impact on the sectors in which they operate." Institutional investors are increasingly focused on private company research and investment opportunities as these firms develop technologies that influence mature sectors, the source added. Nearly 1,500 private startups have achieved unicorn status, having raised funding at valuations above $1 billion, according to PitchBook's tracker. North America leads globally with over 1,000 unicorns, collectively valued at nearly $4 trillion. As private companies play a growing role in transforming legacy industries, Wall Street is adjusting to rising demand for insights into these influential firms, reflecting a shift in how market power is assessed. (Reporting by Nupur Anand in New York and Manya Saini in Bengaluru; Editing by Mohammed Safi Shamsi)
The Sun
9 hours ago
- The Sun
GSK shares drop as US FDA panel rejects blood cancer drug Blenrep
LONDON: GSK shares plunged more than 6% on Friday, hitting the lowest point in Britain's blue-chip FTSE 100 index after a US FDA advisory panel voted against approving its blood cancer drug Blenrep. The panel raised concerns over side effects, dealing a blow to the British drugmaker's efforts to revive the treatment, which was withdrawn from US markets in 2022. At 0807 GMT, GSK shares dropped as much as 7% to 1,315 pence, while the broader FTSE 100 index rose 0.2%. The company had submitted a renewed application based on two late-stage trials showing that Blenrep combination therapies reduced the risk of death and delayed cancer progression. The setback comes as GSK seeks to offset declining sales from its top drugs and vaccines with newer approvals. The company is also preparing for patent expirations in its HIV portfolio starting in 2028. Analysts from Berenberg, JPMorgan, and Barclays predict the FDA is unlikely to approve Blenrep, with a final decision expected next week. While the FDA usually follows advisory panel recommendations, it is not obligated to do so. GSK had previously projected peak annual sales of over 3 billion pounds for Blenrep, with the US expected to be its largest market. However, JPMorgan analysts now suggest the company may need to revise its sales targets and long-term revenue goals. 'GSK remains confident in the benefit/risk profile of Blenrep and will continue to work closely with the FDA as they complete their review,' the company said in a statement. The FDA panel highlighted side effects such as blurred vision, photophobia, and dry eyes, along with concerns over dosing and lack of US patient representation in trials. GSK is set to release its second-quarter earnings report on July 30. - Reuters
The Star
13 hours ago
- The Star
Oil extends gain on Iraq outages, tight market supports
SINGAPORE: Oil prices extended gains on Friday, underpinned by supply concerns following drone attacks on northern Iraqi oilfields and tight market fundamentals amid healthy summer demand. Brent crude futures climbed 29 cents, or 0.40%, to $69.81 a barrel as of 0451 GMT, U.S. West Texas Intermediate crude futures advanced 27 cents, or 0.42%, to $67.81 a barrel. Four days of drone attacks on oilfields in Iraqi Kurdistan that shut down half the region's output have supported prices, pushing both contracts up $1 on Thursday. Additionally, seasonal travel demand has propped up the market. In the first two weeks of July, global oil demand has averaged 105.2 million barrels per day (bpd), up by 600,000 bpd from a year earlier and largely in line with forecast, JPMorgan analysts said in a research note. "Crude prices have been broadly stable this week, with no significant moves as the impact of OPEC+ supply increases has been offset by strong seasonal demand in the U.S.," said LSEG's analyst Anh Pham. U.S. crude inventories fell a larger-than-expected last week as exports rose, government data on Wednesday showed. Demand in Asia also firmed as refineries came back from maintenance amid peak seasonal demand. Near-term oil fundamentals are likely to remain supportive, with the market set to remain fairly tight through this quarter, before becoming better supplied from the last three months of the year, ING analysts said in a note on Friday. Still, the uncertainty around U.S. tariff policy, which appears unlikely to be settled until after August 1, is weighing on the market. Plans by major oil producers to remove output cuts will also add to supply as the seasonal Northern Hemisphere summer demand ends. For this week, both Brent and WTI were down more than 1%. Oil output in the semi-autonomous Kurdistan region has been slashed from about 280,000 bpd to between 140,000 bpd and 150,000 bpd, two energy officials said. Officials pointed to Iran-backed militias as the likely source of attacks this week on the region's oilfields, although no group has claimed responsibility. Despite the attack, Iraq's federal government said on Thursday that Iraqi Kurdistan will resume oil exports through a pipeline to Turkey after a two-year halt. - Reuters
